Drug discoveries & therapeutics最新文献

{"title":"Zhimu-Huangbo ameliorates AQP4 depolarization in diabetic cognitive impairment rats by targeting the serum-derived exosomal TIMP3-mediated MMP9/β-DG pathway.","authors":"Ying Li, Xueling Lin, Jie Bu, Genhui Yang, Lin Niu, Lin Zhang, Dingbin Liu, Yanjun Zhang, Qingsheng Yin, Pengwei Zhuang","doi":"10.5582/ddt.2025.01102","DOIUrl":"10.5582/ddt.2025.01102","url":null,"abstract":"<p><p>Aquaporin-4 (AQP4) depolarization-mediated glymphatic system (GS) dysfunction is a critical pathological mechanism in diabetic cognitive impairment (DCI). However, its underlying mechanism has not been clarified. The Zhimu-Huangbo (ZMHB) herb pair, a classic formulation historically employed in traditional Chinese medicine, demonstrates neuroprotective effects, including the amelioration of cognitive dysfunction. Emerging evidence suggests that the exosomal pathway may regulate abnormalities in diabetes-induced AQP4 polarization. Nevertheless, whether the neuroprotective effects of ZMHB mediate the restoration of AQP4 polarity through the exosomal pathway remains to be elucidated. This study takes the exosomal pathway as the entry point to elucidate the mechanism of AQP4 depolarization in DCI and determine how ZMHB restores AQP4 polarization and improves cognitive function. ZMHB significantly improved cognitive function, effectively restored GS function and maintained AQP4 polarization. Pharmacological blockade of exosomal pathways partially reduced the therapeutic effects of ZMHB, demonstrating that its efficacy depends on exosome-mediated signaling; proteomics combined with western blotting validation revealed tissue inhibitor of metalloproteinase 3 (TIMP3) as a pivotal protein modulated by ZMHB, which restored AQP4 polarization by inhibiting matrix metalloproteinase-9 (MMP9) activity and blocking β-dystroglycan (β-DG) cleavage in astrocytes. In vitro studies further demonstrated that both ZMHB-treated serum exosomes (ZMHB-sExos) and the TIMP3 agonist MPT0B390 restored astrocytic AQP4 polarization by modulating the MMP9/β-DG pathway. We demonstrated that ZMHB restored AQP4 depolarization in DCI rats by modulating the exosomal TIMP3-MMP9/β-DG pathway.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"360-377"},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145777210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II investigator-initiated, continuation trial of 5-aminolevulinic acid hydrochloride/sodium ferrous citrate (5-ALA-HCl/SFC) for patients with adult-onset Still's disease (AOSD) refractory to glucocorticoids.","authors":"Remi Sumiyoshi, Tomohiro Koga, Osamu Kamisawa, Shimpei Morimoto, Naoki Hosogaya, Hiroshi Yamamoto, Makoto Hori, Yosuke Inaba, Yoko Hattori, Tamiki Hikake, Tomoya Kurokawa, Hideki Hanaoka, Shuzo Sato, Kiyoshi Migita, Noriyoshi Ogawa, Motomu Hashimoto, Atsushi Kawakami","doi":"10.5582/ddt.2025.01106","DOIUrl":"10.5582/ddt.2025.01106","url":null,"abstract":"<p><p>The aim of this study is to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride/sodium ferrous citrate (5-ALA-HCl/SFC) in patients with adult-onset Still's disease (AOSD) refractory to glucocorticoids during the maintenance treatment period of a phase II investigator-initiated randomized, double-blind, parallel-group clinical trial. This multicenter, open-label, continuous trial was limited to participants from the preceding study, which was planned for 30 enrollees but was stopped early after four enrollees because of slow recruitment. The current trial maintained a 16-week treatment period and remained double-blind until the previous study database was locked and unblinded. Two dose groups were used: 5-ALA-HCl/SFC 100 and 300 mg. Participants previously assigned to placebo were re-randomized 1:1 to either dose group. The dosage and administration were identical to those of the previous protocol. The primary endpoint was the achievement of adapted ACR 30 at week 16. All four participants achieved the primary endpoints. Secondary outcomes, including the adapted ACR 90/100 and the change in serum ferritin levels, showed numerically greater improvement in the participant who received the high-dose compared with the other. Eleven adverse events occurred in three participants, including one serious event and one discontinuation; all were deemed unrelated to the study drug, and no deaths were reported. This study identified potential efficacy signals, particularly in the high-dose group. However, because of premature termination and a very limited sample size, the data were insufficient to establish the efficacy and safety profile of 5-ALA-HCl/SFC in refractory AOSD. Larger studies are required to confirm these findings.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"404-413"},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disproportionality and time-to-onset analyses of drug-induced weight gain using the Japanese Adverse Drug Event Report database.","authors":"Naohito Ide, Rika Shibata, Ken-Ichi Sako, Tomoji Maeda","doi":"10.5582/ddt.2025.01096","DOIUrl":"10.5582/ddt.2025.01096","url":null,"abstract":"<p><p>Drug-induced weight gain is a clinically important adverse event that can lead to obesity, metabolic syndrome, cardiovascular disease, and reduced treatment adherence. Although several drug classes are known to cause weight gain, the onset timing and underlying mechanisms remain incompletely understood. This study aimed to investigate signals and evaluate time to onset of drug-induced weight gain using the Japanese Adverse Drug Event Report (JADER) database. We analyzed JADER data from April 2004 to June 2025, and in the disproportionality analysis reporting odds ratios with 95% confidence intervals were calculated. Time to onset was also assessed, and Weibull distribution analysis was applied to evaluate onset patterns. Among 975,869 reports, 814 cases of drug-induced weight gain were identified. Signals were detected for known drugs such as antipsychotics, pregabalin, and pioglitazone, as well as for drugs without weight gain listed in their package inserts, including benzodiazepines. Pregabalin showed the earliest median onset at 19 days (early failure), followed by olanzapine and risperidone at 1-2 months, pioglitazone at 2 months, and clozapine at 6 months, all classified as random failure types. This study demonstrated that drug-induced weight gain varies by drug class in both onset timing and mechanisms. These findings underscore the need for careful weight monitoring during treatment, particularly early with pregabalin and long-term with clozapine and pioglitazone. Prospective studies are warranted to clarify causal relationships and clinical implications.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"389-394"},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of imeglimin in older patients with type 2 diabetes: Analysis of a national database and a long-term case suggesting the potential for sarcopenia prevention.","authors":"Atsushi Ishimura, Kaori Hashimoto, Hirofumi Ogino","doi":"10.5582/ddt.2025.01093","DOIUrl":"10.5582/ddt.2025.01093","url":null,"abstract":"<p><p>We aimed to evaluate the clinical significance of imeglimin in older patients with type 2 diabetes. Prescription trends were analyzed using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (2021-2023). Prescriptions for imeglimin increased, with the highest usage among patients in their 70s, followed by those in their 60s, and a clear upward trend in those aged ≥ 80 years. We present the case of an 80-year-old woman with diabetes who repeatedly discontinued treatment. After initiating imeglimin (2000 mg/day), she continued therapy successfully, achieving stable HbA1c levels at approximately 7% over 30 months. Muscle mass indices (creatine kinase, creatinine, and estimated glomerular filtration rate), nutritional status (albumin), and inflammation (C-reactive protein) remained stable, and independent walking and quality of life were preserved. These findings suggest that imeglimin may support glycemic control and may help attenuate frailty and sarcopenia progression in older adults with diabetes.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"431-434"},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulatory effects of ingesting dietary fiber and protein before carbohydrates on postprandial interstitial glucose responses.","authors":"Imanaka Yuko Wada, Sanae Tanaka, Chisato Watanabe, Ken-Ichi Shimokawa, Fumiyoshi Ishii","doi":"10.5582/ddt.2025.01099","DOIUrl":"10.5582/ddt.2025.01099","url":null,"abstract":"<p><p>Rapid postprandial elevations in interstitial glucose contribute to the progression of type 2 diabetes and associated vascular complications. Nutritional sequencing strategies, such as consuming dietary fiber or protein before carbohydrate intake, have been proposed to attenuate glucose excursions by delaying gastric emptying, stimulating incretin secretion, and enhancing insulin responsiveness. However, observational evidence under real-world conditions remains scarce in both healthy individuals and those with diabetes. We performed an observational study including healthy participants and individuals with type 2 diabetes. All participants were equipped with a continuous glucose monitoring system (FreeStyle Libre™) for 14 days to capture interstitial glucose profiles under daily living conditions. Participants simultaneously recorded dietary intake and meal timing. Postprandial glucose excursions were evaluated by comparing carbohydrate ingestion alone with ingestion preceded by fiber and/or protein. Preceding carbohydrate intake with dietary fiber or protein was associated with significant attenuation of postprandial glucose excursions compared with carbohydrate alone. This effect was particularly evident within the first 120 minutes after eating and was most pronounced when fiber and protein were consumed in combination. Attenuation occurred in both healthy individuals and participants with type 2 diabetes, though the magnitude of suppression varied across groups. Our findings indicate that consuming fiber and protein prior to carbohydrate intake can substantially mitigate rapid postprandial glucose rises. These results support the physiological rationale for macronutrient sequencing and underscore the potential of simple, practical dietary strategies to improve glycemic control in daily life among both healthy individuals and those with diabetes.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"425-430"},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TRPC6 expression is negatively correlated with breast cancer progression.","authors":"Yifei Ma, Guoning Li, Haoyang Yu, Baoke Wang, Zhihan Diao, Yuan Du, Hongbo Wang, Huiping Liu","doi":"10.5582/ddt.2025.01082","DOIUrl":"10.5582/ddt.2025.01082","url":null,"abstract":"<p><p>The transient receptor potential channel 6 (TRPC6), a Ca²⁺-permeable, non-selective cation channel, is a potential drug target widely expressed in most human tissues. However, the role of TRPC6 in breast cancer remains largely unknown. We comprehensively investigated the relationships between TRPC6 and breast cancer using online databases, including TIMER, cBioPortal, UALCAN, the Kaplan-Meier plotter, the Human Protein Atlas, STRING, and the LinkedOmics, to evaluate the prognostic value of TRPC6. We also tentatively explored the effects of TRPC6 modulation on proliferation and metastasis potential in several breast cancer cell lines by MTT assay, colony formation assay, flow cytometry, and scratch wound healing assay. The TCGA data showed lower TRPC6 gene expression in breast tumours versus normal breast tissues. The Human Protein Atlas revealed that the TRPC6 protein was generally expressed at low levels in both normal and breast carcinoma tissue. The Kaplan-Meier plotter showed that the low TRPC6 level is correlated with worse relapse-free survival probability in breast cancer. Moreover, the TRPC6 gene was linked to immune infiltration in breast cancer, and this relationship affected the prognosis of breast cancer. In contrast to published researches, we found that TRPC6 expression was negatively correlated with breast cancer cell proliferation and metastasis abilities, suggesting TRPC6 as a promising prognostic biomarker for breast cancer, where low expression of TRPC6 was related to worse prognoses. This research raises the necessity of rethinking the mechanism perspective and targetability of TRPC6 in breast cancer, which warrants further investigation.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"325-336"},"PeriodicalIF":0.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing gene-targeting efficiency of Agrobacterium tumefaciens-mediated transformation and electroporation in the pathogenic fungus Trichosporon asahii JCM2466.","authors":"Yasuhiko Matsumoto, Mei Nakayama, Yuta Shimizu, Sachi Koganesawa, Hiromi Kanai, Wakako Hayashi, Toma Matsuo, Tsuyoshi Yamada, Takashi Sugita","doi":"10.5582/ddt.2025.01084","DOIUrl":"10.5582/ddt.2025.01084","url":null,"abstract":"<p><p>Trichosporon asahii is a pathogenic fungus that causes severe deep-seated fungal infections in neutropenic patients. Ku70, a key component of the non-homologous end-joining (NHEJ) pathway involved in the repair of DNA double-strand breaks, influences gene-targeting efficiency in T. asahii MPU129 strain using electroporation, a gene transfer method. Although phenotypic traits such as morphology and biofilm formation vary among T. asahii strains, the impact of different gene transfer methods on gene-targeting efficiency remains poorly characterized. In this study, we compared the gene-targeting efficiency of Agrobacterium tumefaciens-mediated transformation (ATMT) and electroporation. In T. asahii JCM2466 (CBS2479), a strain with high hyphal-forming ability, the ku70 gene-deficient mutant exhibited a higher gene-targeting efficiency via ATMT than the wild-type strain when generating a cnb1 gene-deficient mutant. The cnb1 gene encodes the β-subunit of calcineurin. In contrast, in the ku70 gene-deficient background of T. asahii JCM2466, cnb1-deficient mutants could not be generated by electroporation. The gene-targeting efficiencies of ATMT and electroporation in the ku70 gene-deficient mutant of T. asahii JCM2466 were 18% and 0%, respectively. The cnb1 gene-deficient mutants exhibited sensitivity to high temperature and several stress-inducing compounds. These results suggest that ATMT is a suitable gene transfer method for generating gene-deficient mutants in the ku70-deficient T. asahii JCM2466 background. Therefore, the choice of gene transfer method should be carefully tailored to the genetic background and phenotypic characteristics of each T. asahii strain.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"337-345"},"PeriodicalIF":0.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paltusotine: The first selective nonpeptide agonist of somatostatin receptor 2 (SSTR2) for the treatment of acromegaly.","authors":"Yueyi Sun, Daoran Lu, Jianjun Gao","doi":"10.5582/ddt.2025.01109","DOIUrl":"10.5582/ddt.2025.01109","url":null,"abstract":"<p><p>Acromegaly is an endocrine disorder characterized by abnormal enlargement of the extremities and internal organs resulting from excessive secretion of growth hormone (GH) by the pituitary gland, which in turn leads to elevated levels of insulin-like growth factor 1 (IGF-1). Approximately 45% of patients remain biochemically uncontrolled after surgery and require long-term treatment with injectable somatostatin analogs such as octreotide or lanreotide. These polypeptide drugs generally require monthly administration to maintain disease control; however, many patients experience recurrence of symptoms towards the end of the dosing interval. Moreover, injection-site pain and local reactions are common, significantly impacting patients' quality of life. On September 25, 2025, the U.S. Food and Drug Administration (FDA) approved paltusotine, the first once-daily oral, nonpeptide somatostatin receptor 2 (SSTR2) agonist for the treatment of acromegaly. By enabling oral rather than injectable therapy, paltusotine reduces the treatment burden and enhances patient adherence. With its rapid onset and durable biochemical control, this novel agent has the potential to reshape the current paradigm of acromegaly pharmacotherapy and offer patients a more convenient and effective treatment option. Nevertheless, its long-term safety and efficacy warrant further evaluation in real-world clinical settings.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"358-359"},"PeriodicalIF":0.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indicators of a moist wound environment and care to maintain a moist environment for early healing: A scoping review.","authors":"Mao Kunimitsu, Karin Izumi, Yume Kawamizu, Kenshin Takezawa, Kanon Nishida, Hitomi Honda, Yuri Maeda, Rena Yamauchi, Risa Yoshida, Yukari Nakajima, Amika Yamada, Kanae Mukai, Makoto Oe","doi":"10.5582/ddt.2025.01083","DOIUrl":"10.5582/ddt.2025.01083","url":null,"abstract":"<p><p>Although maintaining a moist environment is important for wound healing, excess moisture can delay wound healing. Furthermore, recommended assessment methods for moist environments in the latest consensus guidelines are subjective. This scoping review aimed to map indicators to assess the moist environment in a wound and summarize the effectiveness of wound healing care in maintaining a moist environment, as assessed using these indicators. We searched four databases, the Medical Literature Analysis and Retrieval System On-Line, Cumulative Index to Nursing and Allied Health Literature, PubMed, and the Japan Medical Abstracts Society database, using a combination of chronic wound- and moisture-related terms. Independent researchers screening the articles based on the inclusion criteria and extracting relevant data afterward. After screening 2,727 articles, eight met the inclusion criteria: original articles/case studies, studies involving patients with chronic wounds, studies on care to maintain a moist wound environment, and studies assessing wound healing and moist wound environment. The articles included in this review demonstrated that dressings that absorb or hydrate exudates and care decisions based on the moisture content of the wound surface were effective care strategies for wound healing. Additional research is required to determine the best objective indicator for the assessment of a moist wound environment because despite the numerous existing indicators, only few reference values for healing have been reported.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"285-293"},"PeriodicalIF":0.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Purification and characterization of a novel antioxidant protein from Arca subcrenata Lischke.","authors":"Qing Yan, Hui Shi, Yue Gao, Chunlei Li, Lin Dong, Jianhua Zhu, Rongmin Yu","doi":"10.5582/ddt.2025.01053","DOIUrl":"10.5582/ddt.2025.01053","url":null,"abstract":"<p><p>A novel protein, G1H2GC2, was isolated from Arca subcrenata Lischke using homogenization and ammonium sulfate precipitation, and further purified by several column chromatography techniques including diethyl-aminoethanol (DEAE) Sepharose Fast Flow anion exchange, gel filtration chromatography (Sephadex G-25), Phenyl Sepharose CL-4B hydrophobic chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC). The purity of G1H2GC2 was over 97% in RP-HPLC, and its high purity was further verified by the appearance of a single band on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The protein content of G1H2GC2 was found to be over 99% by Bradford assay. The molecular weight was determined as 25.6 kDa by electrospray ionization-mass spectrometry (ESI-MS/MS). The isoelectric point of G1H2GC2 was measured to be 7.71 by isoelectric focusing-polyacrylamide gel electrophoresis (IEF-PAGE). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS/MS) was employed to detect and identify the protein by mass fingerprinting coupled with fragmentation patterns. No matched protein was found, confirming that G1H2GC2 was a novel protein. An attempt was made to detect the N-terminal amino acid sequence of G1H2GC2 by Edman degradation, but the sequence of G1H2GC2 was found to be blocked. The scavenging percentage of G1H2GC2 at 15 mg/mL against 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS^•+) was 52.84%. The median effective concentration (EC₅₀) value of G1H2GC2 against ABTS^•+ was 17.67 mg/mL. The results showed that G1H2GC2 might be developed as a potential food additive agent.</p>","PeriodicalId":520606,"journal":{"name":"Drug discoveries & therapeutics","volume":" ","pages":"304-313"},"PeriodicalIF":0.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}